PGx-Passport:用于先发性药物基因组检测的可操作胚系遗传变异组合
基于荷兰药物基因组学工作组(DPWG)可操作指南,采用预设标准(等位基因人群频率、对蛋白功能影响、与药物反应关联)系统筛选胚系变异等位基因,构建了包含14个基因(CYP2B6、CYP2C9、CYP2C19、CYP2D6、CYP3A5、DPYD、F5、HLA-A、HLA-B、NUDT15、SLCO1B1、TPMT、UGT1A1、VKORC1)中58个变异等位基因的PGx-Passport组合,可联合DPWG指南优化49种常用处方药的用药。
要点
- PGx-Passport涵盖14个基因的58个胚系变异等位基因,基于DPWG可操作指南筛选。
- 该组合可联合DPWG指南优化49种常用处方药的处方决策。
- 标准化组合有助于促进PGx检测的采纳、交换和连续性。
核心结论
- 基于DPWG可操作指南成功构建了包含58个胚系变异等位基因、覆盖14个基因的PGx-Passport组合。
- 该组合可联合DPWG指南用于优化49种常用处方药的用药。
研究设计与样本
- 研究基于荷兰药物基因组学工作组(DPWG)的可操作临床指南,采用预设标准系统筛选胚系变异等位基因以构建PGx-Passport组合。
- 筛选标准涉及等位基因人群频率、对蛋白功能的影响以及与药物反应的关联。
主要发现
- PGx-Passport包含58个胚系变异等位基因,分布于14个基因:CYP2B6、CYP2C9、CYP2C19、CYP2D6、CYP3A5、DPYD、F5、HLA-A、HLA-B、NUDT15、SLCO1B1、TPMT、UGT1A1和VKORC1。
- 该组合可联合DPWG指南优化49种常用处方药的处方。
关键数值与推荐
- PGx-Passport包含14个基因中的58个胚系变异等位基因。
- 该组合可联合DPWG指南优化49种常用处方药的用药。
临床怎么用
- 临床可采用PGx-Passport进行先发性药物基因组检测,并联合DPWG指南解读结果以优化49种常用处方药的处方。
- 标准化组合有助于促进PGx检测在临床实践中的采纳、交换和连续性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pre-emptive pharmacogenetics (PGx) testing of a panel of germline genetic variants represents a new model for personalized medicine. Clinical impact of PGx testing is maximized when all variant alleles for which actionable clinical guidelines are available are included in the test panel. However, no such standardized panel has been presented to date, impeding adoption, exchange, and continuity of PGx testing. We, therefore, developed such a panel, hereafter called the PGx-Passport, based on the actionable Dutch Pharmacogenetics Working Group (DPWG) guidelines. Germline-variant alleles were systematically selected using predefined criteria regarding allele population frequencies, effect on protein functionality, and association with drug response. A PGx-Passport of 58 germline variant alleles, located within 14 genes (CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A5, DPYD, F5, HLA-A, HLA-B, NUDT15, SLCO1B1, TPMT, UGT1A1, and VKORC1) was composed. This PGx-Passport can be used in combination with the DPWG guidelines to optimize drug prescribing for 49 commonly prescribed drugs.
引用
- van der Wouden CH, van Rhenen MH, Jama WOM, et al. Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing. Clin Pharmacol Ther. 2019. PMID: 31038729. doi:10.1002/cpt.1489
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。